. Verbania, G. Poggio, and . Bottari, Venezia: E Raise, F Ebo

R. Cavassini, M. Dubs, L. Egger, M. Elzi, M. Fischer et al., President of the SHCS, Centre Hospitalier Universitaire Vaudois, CH-1011-Lausanne), H. Furrer (Chairman of the Clinical and Laboratory Committee, Chairman of the Scientific Board

L. A. Gras, A.I. van Sighem (senior researcher), C. Smit (epidemiologist), F. de Wolf (director) Treating physicians (*Site coordinating physicians) Academisch Medisch Centrum bij de Universiteit van Amsterdam -Amsterdam: Dr, J.M. Prins*, Dr. J. Branger, Dr. J.K.M
URL : https://hal.archives-ouvertes.fr/hal-00420991

M. E. Vrouenraets, . M. Dr, D. F. Van-vugt, . G. Wit-dr, *. Schreij et al., Academisch Ziekenhuis Maastricht - Maastricht Catharina Ziekenhuis -Eindhoven: Dr

*. Kauffmann, D. K. Pogány, and . Isala-klinieken-zwolle, Kennemer Gasthuis -Haarlem: Prof, Prof. dr. P.J. van den Broek

E. F. Schippers-dr, *. Vriesendorp, D. F. Jeurissen-dr, *. Van-houte, . M. Dr et al., Medisch Centrum Leeuwarden -Leeuwarden Onze Lieve Vrouwe Gasthuis - Amsterdam, Prof. dr. K. Brinkman*, Drs. G.E.L. van den Berk, Dr. W.L. Blok, Dr. P.H.J

. Wagenaar and . St, Elisabeth Ziekenhuis -Tilburg: Dr, J.R. Juttmann*, Dr. C

M. E. Van-kasteren and . St, Lucas Andreas Ziekenhuis -Amsterdam: Dr

. Vasmel, . Universitair-medisch-centrum, and . St, Radboud -Nijmegen: Dr, P.P. Koopmans*

D. M. Back, D. H. Bakker, . P. Zaaijer-dr, and D. K. Rietra, Onze Lieve Vrouwe Gasthuis -Amsterdam Slotervaart Ziekenhuis - Amsterdam, Prof. dr. B. Berkhout, Dr. S. Jurriaans. CLB Stichting Sanquin Bloedvoorziening -Amsterdam: Dr. Th. Cuijpers

C. L. Jansen, H. Streeklaboratorium-twente-enschede, D. J. Storm, D. J. Weel, and . Van-zeijl, Laboratorium voor de Volksgezondheid in Friesland -Leeuwarden: Dr Leids Universitair Medisch Centrum -Leiden, Universitair Medisch Centrum St. Radboud -Nijmegen: Prof. dr. J.M.D. Galama, Dr. W.J.G. Melchers, Dr. Verduyn- Lunel. Erasmus MC -Rotterdam: Dr. G.J.J. van Doornum, Dr. H.G.M. Niesters, Prof. dr

F. Katlama, P. Hôpital-de-la-pitié-salpétière, H. Viard, P. Necker-enfants-malades, P. Girardantoine et al., Hungary (D Banhegyi) Szent Lásló Hospital, Budapest. Ireland (F Mulcahy) St. James's Hospital, Dublin. Israel (I Yust), Medizinische Hochschule Hannover. Greece (J Kosmidis) Athens General Hospital Rambam Medical Center

A. Medisch-centrum-bij-de-universiteit-van-amsterdam, A. Norway, . Bruun, . Maeland, . Wroclaw et al., Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical University, Gdansk. Portugal (F Antunes) E Valadas, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Matez, Hospital Curry Cabral The Institute for Infectious and Tropical Diseases, Belgrade. Slovakia (M Mokrá?) D Staneková, Dérer Hospital, Lisbon. Romania (D Duiculescu) Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest; A Streinu-Cercel, Institute of Infectious Diseases Medical Academy Botkin Hospital Bratislava. Spain (J González-Lahoz) Hospital Carlos III Hospital Germans Trias i Pujol

A. Field-coordinator, . Alquézar, . Ceeiscat, C. Ciber-epidemiología-y-salud-pública, and . Spain, Steering committee J

J. Murillas, Hospital Son Dureta de Mallorca) Scientific committee A

M. Riera, Hospital Son Dureta de Mallorca) F

G. Segura and . Navarro, Corporació Parc Taulí de Sabadell); L. Force, Hospital de Mataró

J. Vilaró, Hospital de Vic); A. Masabeu (Hospital de Palamós); I García, Hospital General d´Hospitaletd´Hospitalet

M. Guadarrama, Hospital Alt Penedès de Vilafranca

F. Aquitaine-cohort-(-geneviève-chêne, F. Dabis, R. Thiebaut, and B. Masquelier, French Hospital Database, Lyon Primary Infection cohort (Philippe Vanhems), SEROCO cohort

V. Delpech, S. Lattimore, G. Murphy, and J. Parry, Ruslan Malyuta) United Kingdom Edinburgh Hospital cohort, Ukraine Perinatal Prevention of AIDS Initiative Health Protection Agency Royal Free haemophilia cohort (Caroline Sabin, Christine Lee), UK Register of HIV Seroconverters (Kholoud Porter

. Web, Hazard ratios comparing deferring cART to a lower CD4 range with starting in a higher CD4 range, among patients with presumed transmission via IDU

M. Egger, B. Hirschel, P. Francioli, P. Sudre, M. Wirz et al., Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study, BMJ, vol.315, issue.7117, pp.3151194-3151203, 1997.
DOI : 10.1136/bmj.315.7117.1194

F. Palella, K. Delaney, A. Moorman, M. Loveless, J. Fuhrer et al., Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection, New England Journal of Medicine, vol.338, issue.13, pp.853-908, 1998.
DOI : 10.1056/NEJM199803263381301

S. Hammer, K. Squires, M. Hughes, J. Grimes, L. Demeter et al., A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less, New England Journal of Medicine, vol.337, issue.11, pp.725-758, 1997.
DOI : 10.1056/NEJM199709113371101

S. Cole, M. Hernan, J. Robins, K. Anastos, J. Chmiel et al., Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models, American Journal of Epidemiology, vol.158, issue.7, pp.687-94, 2003.
DOI : 10.1093/aje/kwg206

J. Sterne, M. Hernan, B. Ledergerber, K. Tilling, R. Weber et al., Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study, The Lancet, vol.366, issue.9483, pp.378-84, 2005.
DOI : 10.1016/S0140-6736(05)67022-5

W. El-sadr, J. Lundgren, J. Neaton, F. Gordin, D. Abrams et al., CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, vol.355, issue.22, pp.2283-96, 2006.

S. Emery, J. Neuhaus, A. Phillips, A. Babiker, C. Cohen et al., Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, J Infect Dis, vol.197, issue.8, pp.1133-1177, 2008.

R. Hogg, B. Yip, K. Chan, E. Wood, K. Craib et al., Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy, JAMA, vol.286, issue.20, pp.2568-77, 2001.
DOI : 10.1001/jama.286.20.2568

A. Phillips, S. Staszewski, R. Weber, O. Kirk, P. Francioli et al., HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load, JAMA, vol.286, issue.20, pp.2560-2567, 2001.
DOI : 10.1001/jama.286.20.2560

M. Egger, M. May, G. Chêne, A. Phillips, B. Ledergerber et al., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies, The Lancet, vol.360, issue.9327, pp.119-148, 2002.
DOI : 10.1016/S0140-6736(02)09411-4

R. Pomerantz, Initiating Antiretroviral Therapy During HIV Infection, JAMA, vol.286, issue.20, pp.2597-2606, 2001.
DOI : 10.1001/jama.286.20.2597

S. Cole, R. Li, K. Anastos, R. Detels, M. Young et al., Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies, Statistics in Medicine, vol.157, issue.21, pp.3351-63, 2004.
DOI : 10.1002/sim.1579

M. Prins, A. Hernandez, I. Brettle, R. Robertson, J. Broers et al., Pre-AIDS mortality from natural causes associated with HIV disease progression, AIDS, vol.11, issue.14, pp.1747-56, 1997.
DOI : 10.1097/00002030-199714000-00012

E. Wood, J. Montaner, B. Yip, M. Tyndall, M. Schechter et al., Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users, CMAJ, vol.169, issue.7, pp.656-61, 2003.

J. Sterne, M. May, C. Sabin, A. Phillips, D. Costagliola et al., Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients, J Acquir Immune Defic Syndr, vol.46, issue.5, pp.607-622, 2007.

R. Kaslow, D. Ostrow, R. Detels, J. Phair, B. Polk et al., THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTS, American Journal of Epidemiology, vol.126, issue.2, pp.310-318, 1987.
DOI : 10.1093/aje/126.2.310

B. Ledergerber, V. Overbeck, J. Egger, M. Luethy, and R. , The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics, Sozial- und Pr??ventivmedizin, vol.340, issue.6, pp.387-94, 1994.
DOI : 10.1007/BF01299670

S. Grabar, C. Pradier, C. Le, R. Lancar, C. Allavena et al., Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor, AIDS, vol.14, issue.2, pp.141-150, 2000.
DOI : 10.1097/00002030-200001280-00009

C. Binquet, G. Chene, H. Jacqmin-gadda, V. Journot, V. Saves et al., Modeling Changes in CD4-positive T-Lymphocyte Counts after the Start of Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections The Aquitaine Cohort, 1996???1997, American Journal of Epidemiology, vol.153, issue.4, pp.386-93, 1996.
DOI : 10.1093/aje/153.4.386

W. De, J. Lange, J. Houweling, R. Coutinho, P. Schellekens et al., Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men, J Infect Dis, vol.158, issue.3, pp.615-637, 1988.

A. Mocroft, M. Gill, W. Davidson, and A. Phillips, Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor, AIDS, vol.12, issue.16, pp.2161-2168, 1998.
DOI : 10.1097/00002030-199816000-00011

K. Porter, A. Babiker, K. Bhaskaran, J. Darbyshire, P. Pezzotti et al., Determinants of survival following HIV-1 seroconversion after the introduction of HAART, Lancet, vol.362, issue.9392, pp.1267-74, 2003.

M. Egger, M. May, G. Chene, A. Phillips, B. Ledergerber et al., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies, The Lancet, vol.360, issue.9327, pp.119-148, 2002.
DOI : 10.1016/S0140-6736(02)09411-4

M. May, P. Royston, M. Egger, A. Justice, and J. Sterne, Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy, Statistics in Medicine, vol.23, issue.15, pp.2375-98, 2003.
DOI : 10.1002/sim.1825

M. May, K. Porter, J. Sterne, P. Royston, and M. Egger, Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data, Journal of Clinical Epidemiology, vol.58, issue.10, pp.1033-1074, 2005.
DOI : 10.1016/j.jclinepi.2005.02.015

L. Gras, A. Kesselring, J. Griffin, A. Van-sighem, C. Fraser et al., CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.45, issue.2, pp.183-92, 2007.
DOI : 10.1097/QAI.0b013e31804d685b

D. Arminio, M. Lepri, A. Rezza, G. Pezzotti, P. Antinori et al., Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients, AIDS, vol.14, issue.5, pp.499-507, 2000.

H. Brodt, B. Kamps, P. Gute, B. Knupp, S. Staszewski et al., Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy, AIDS, vol.11, issue.14, pp.1731-1739, 1997.
DOI : 10.1097/00002030-199714000-00010

G. Fatkenheuer, A. Theisen, J. Rockstroh, T. Grabow, C. Wicke et al., Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients, AIDS, vol.11, issue.14, pp.113-116, 1997.
DOI : 10.1097/00002030-199714000-00001

S. Becker, S. Raffanti, N. Hansen, J. Fusco, G. Fusco et al., Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.1, pp.72-81, 2001.
DOI : 10.1097/00126334-200101010-00011

R. Chen, N. Accortt, A. Westfall, M. Mugavero, J. Raper et al., Distribution of Health Care Expenditures for HIV-Infected Patients, Clinical Infectious Diseases, vol.42, issue.7, pp.1003-1013, 2006.
DOI : 10.1086/500453

S. Fultz, M. Skanderson, L. Mole, N. Gandhi, K. Bryant et al., Development and Verification of a ???Virtual??? Cohort Using the National VA Health Information System, Medical Care, vol.44, issue.Suppl 2, pp.25-30, 2006.
DOI : 10.1097/01.mlr.0000223670.00890.74

A. Mocroft, S. Barry, C. Sabin, A. Lepri, S. Kinloch et al., The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997, AIDS, vol.13, issue.10, pp.1255-61, 1999.
DOI : 10.1097/00002030-199907090-00016

R. Hogg, B. Yip, C. Kully, K. Craib, O. Shaughnessy et al., Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens, CMAJ, vol.160, issue.5, pp.659-65, 1999.

A. Jaen, J. Casabona, A. Esteve, J. Miro, C. Tural et al., Caracter??sticas clinicoepidemiol??gicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infecci??n por el virus de la inmunodeficiencia humana. Cohorte PISCIS, Medicina Cl??nica, vol.124, issue.14, pp.525-556, 2005.
DOI : 10.1157/13073938

J. Lundgren, A. Phillips, S. Vella, C. Katlama, B. Ledergerber et al., Regional differences in use of antiretroviral agents and primary prophylaxis, p.3122

H. European and . Patients, EuroSIDA Study Group, J Acquir.Immune.Defic.Syndr.Hum.Retrovirol, vol.16, issue.3, pp.153-60, 1997.

D. Rubin, Multiple Imputation for Nonresponse in Surveys, 1987.
DOI : 10.1002/9780470316696

M. May, J. Sterne, C. Sabin, D. Costagliola, A. Justice et al., Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies, AIDS, vol.21, issue.9, pp.1185-97, 2007.

F. Palella, J. Knoll, M. Chmiel, J. Moorman, A. Wood et al., Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4^+ Cell Strata, Annals of Internal Medicine, vol.138, issue.8, pp.620-626, 2003.
DOI : 10.7326/0003-4819-138-8-200304150-00007

T. Sterling, R. Chaisson, and R. Moore, : Disease Progression, Treatment Durability, and Drug Toxicity, Clinical Infectious Diseases, vol.36, issue.6, pp.812-817, 2003.
DOI : 10.1086/367934

A. Jaen, A. Esteve, J. Miro, C. Tural, A. Montoliu et al., Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain), J Acquir Immune Defic Syndr, vol.47, issue.2, pp.212-232, 2008.

S. Hammer, M. Saag, M. Schechter, J. Montaner, R. Schooley et al., Treatment for Adult HIV Infection, JAMA, vol.296, issue.7, pp.827-870, 2006.
DOI : 10.1001/jama.296.7.827

P. Braitstein, M. Brinkhof, F. Dabis, M. Schechter, A. Boulle et al., Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries, Lancet, vol.367, issue.9513, pp.817-841, 2006.

H. Masur, Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex Disease in Patients Infected with the Human Immunodeficiency Virus, New England Journal of Medicine, vol.329, issue.12, pp.898-904, 1993.
DOI : 10.1056/NEJM199309163291228

M. Seligmann, D. Warrell, J. Aboulker, C. Carbon, J. Darbyshire et al., Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection, Lancet, vol.343, pp.871-81, 1994.

D. Coordinating and C. , Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals, Lancet, vol.348, issue.9023, pp.283-91, 1996.

R. Moore, J. Keruly, K. Gebo, and G. Lucas, An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002, J Acquir Immune Defic Syndr, vol.39, issue.2, pp.195-203, 2005.

F. Lampe, J. Gatell, S. Staszewski, M. Johnson, C. Pradier et al., Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy, Archives of Internal Medicine, vol.166, issue.5, pp.521-529, 1996.
DOI : 10.1001/archinte.166.5.521

E. Wood, R. Hogg, P. Harrigan, and J. Montaner, When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients, The Lancet Infectious Diseases, vol.5, issue.7, pp.407-421, 2005.
DOI : 10.1016/S1473-3099(05)70162-6

A. Phillips, B. Gazzard, N. Clumeck, M. Losso, and J. Lundgren, When should antiretroviral therapy for HIV be started?, BMJ, vol.334, issue.7584, pp.76-84, 2007.
DOI : 10.1136/bmj.39064.406389.94

T. Chun and A. Fauci, Latent reservoirs of HIV: Obstacles to the eradication of virus, Proceedings of the National Academy of Sciences, vol.96, issue.20, pp.10958-61, 1999.
DOI : 10.1073/pnas.96.20.10958

A. Carr, K. Samaras, A. Thorisdottir, G. Kaufmann, D. Chisholm et al., Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study, The Lancet, vol.353, issue.9170, pp.2093-2102, 1999.
DOI : 10.1016/S0140-6736(98)08468-2

S. Grinspoon and A. Carr, Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults, New England Journal of Medicine, vol.352, issue.1, pp.48-62, 2005.
DOI : 10.1056/NEJMra041811

A. Monforte, A. Lepri, A. Rezza, G. Pezzotti, P. Antinori et al., Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na??ve patients, AIDS, vol.14, issue.5, pp.499-507, 2000.
DOI : 10.1097/00002030-200003310-00005

N. Friis-moller, C. Sabin, R. Weber, M. Arminio, E. Sadr et al., Combination antiretroviral therapy and the risk of myocardial infarction, N.Engl.J.Med, vol.349, issue.21, pp.1993-2003, 2003.

N. Friis-moller, P. Reiss, C. Sabin, R. Weber, A. Monforte et al., Class of antiretroviral drugs and the risk of myocardial infarction, N.Engl.J.Med, vol.356, issue.17, pp.1723-1758, 2007.

D. Nolan and S. Mallal, Antiretroviral-therapy-associated lipoatrophy: current status and future directions, Sexual Health, vol.2, issue.3, pp.153-63, 2005.
DOI : 10.1071/SH04058

A. Mocroft, R. Brettle, O. Kirk, A. Blaxhult, J. Parkin et al., Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study, AIDS, vol.16, issue.12, pp.1663-71, 2002.
DOI : 10.1097/00002030-200208160-00012

A. Phillips, J. Neaton, and J. Lundgren, The role of HIV in serious diseases other than AIDS, AIDS, vol.22, issue.18, pp.2409-2427, 2008.
DOI : 10.1097/QAD.0b013e3283174636

H. Lane and J. Neaton, When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data, Annals of Internal Medicine, vol.138, issue.8, pp.680-681, 2003.
DOI : 10.7326/0003-4819-138-8-200304150-00018

M. Schechter, Therapy for Early HIV Infection: How Far Back Should the Pendulum Swing?, The Journal of Infectious Diseases, vol.190, issue.6, pp.1043-1048, 2004.
DOI : 10.1086/422852

D. Ho, Time to Hit HIV, Early and Hard, New England Journal of Medicine, vol.333, issue.7, pp.450-451, 1995.
DOI : 10.1056/NEJM199508173330710

W. Burman, R. Reves, and D. Cohn, The Case for Conservative Management of Early HIV Disease, JAMA, vol.280, issue.1, pp.93-98, 1998.
DOI : 10.1001/jama.280.1.93

S. Holmberg, F. Palella, J. Lichtenstein, K. Havlir, and D. , The Case for Earlier Treatment of HIV Infection, Clinical Infectious Diseases, vol.39, issue.11, pp.1699-704, 2004.
DOI : 10.1086/425743

S. Hammer, J. Eron, J. Reiss, P. Schooley, R. Thompson et al., Antiretroviral Treatment of Adult HIV Infection, JAMA, vol.300, issue.5, pp.555-70, 2008.
DOI : 10.1001/jama.300.5.555

N. Clumeck, A. Pozniak, and F. Raffi, European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults, HIV Medicine, vol.9, issue.2, pp.65-71, 2008.
DOI : 10.1086/426589

A. Phillips, D. Dunn, C. Sabin, A. Pozniak, R. Matthias et al., Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice, AIDS, vol.19, issue.5, pp.487-94, 2005.

C. Cox, H. Chu, M. Schneider, and A. Munoz, Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution, Statistics in Medicine, vol.24, issue.23, pp.4352-74, 2007.
DOI : 10.1002/sim.2836